Monrol
- Company typePrivate
- Founded1994
- HeadquartersBeykoz
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Monrol does
Monrol, which now operates under the Curium Pharma brand (previously known as Monrol), is a global nuclear medicine and radiopharmaceutical company headquartered with dual global headquarters in Boston, USA and Paris, France. The company develops, manufactures, and distributes a portfolio of more than 50 products spanning generators, hot products, cold kits, and auxiliary supplies used in PET and SPECT imaging as well as targeted radioligand therapy for oncology, cardiology, and neurology applications.
Its core technology base is a vertically integrated radiopharmaceutical manufacturing and distribution network that includes one molybdenum processing facility, 80 manufacturing sites, and more than 45 PET and SPECT nuclear pharmacies serving 70+ countries. Curium operates the full radiopharmaceutical value chain — from isotope processing through to last-mile delivery to hospital nuclear medicine departments — and serves 6,000+ customers worldwide, reaching approximately 14 million patients annually and producing €1bn of revenue in 2025 with a workforce of 3,800+.
The business model is a direct enterprise field-sales motion to hospitals, medical facilities, and nuclear medicine departments, with delivery carried out through company-owned radiopharmacies and manufacturing sites. The company is privately held by CapVest following a November 2025 recapitalization described as the largest transaction in the global nuclear medicine industry, and as of mid-2026 had announced a definitive merger agreement with Lantheus and the acquisition of Abscint SA, both of which would materially reshape its scale and pipeline.
Monrol firmographics
Firmographics- Name
- Monrol
- Legal name
- Curium Pharma
- Website
- https://monrol.com.tr
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Monrol industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)
- akta.pro secondary industries
- Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Radiopharmaceutical & Nuclear Medicine Distributors (HLAIAJAI)
Keywords
Where Monrol is headquartered
LocationHeadquarters
- HQ city
- Beykoz
Offices25 records
Markets served
Monrol business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Radiopharmaceutical Products: Sale of nuclear medicine products including generators, cold kits, hot products and auxiliary products used in diagnosis and treatment of diseases
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Monrol product offering
Product offeringCore offering
Monrol (operating as Curium Pharma) is a global nuclear medicine company that develops, manufactures, and distributes radiopharmaceuticals for diagnosis and treatment of cancer, cardiovascular, and neurological diseases. Its product portfolio includes radioactive generators, ready-to-use hot products, cold kits for compounding, PET and SPECT imaging agents, targeted radioligand therapies, and auxiliary products. The company operates the world's largest vertically integrated radiopharmaceutical manufacturing network — spanning one molybdenum-99 processing facility, 80 manufacturing sites, and 45+ radiopharmacies across the US and Europe — delivering time-sensitive radiopharmaceuticals to hospitals and nuclear medicine departments in 70+ countries.
Product overview
Curium Pharma is a global radiopharmaceutical company offering a comprehensive portfolio of nuclear medicine products organized into diagnostic and therapeutic categories. The product portfolio centers on generators (including moly processing), hot products, cold kits, and auxiliary products, spanning PET and SPECT imaging modalities. The company operates the world's largest vertically-integrated manufacturing network in radiopharmaceuticals, with 1 molybdenum processing plant, 80 manufacturing sites, and 45+ radiopharmacies across the globe. Key products include Thallous Chloride TI 201 Injection for cardiac imaging, 64Cu-PSMA-I&T for prostate cancer PET imaging, and targeted radioligand therapies for neuroendocrine tumors and other cancers. The portfolio includes over 50 products distributed across 70+ countries, serving 14 million patients annually.
Differentiator
Problem solved
Functional benefit
Products and services
- Radioactive Generators
- Hot Products
- Cold Kits
- Auxiliary Products
- PET Radiopharmaceuticals
- SPECT Radiopharmaceuticals
- Thallous Chloride TI 201 Injection
- 64Cu-PSMA-I&T
- Targeted Radioligand Therapy (RLT)
- Xenon Xe 133 Gas
Quantifiable outcome
- 14 million patients served annually
- +2 more outcomes
Companies that use Monrol
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles1 record
Monrol technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Monrol partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, flagship and minor.
- Abscint SAcoreCurium acquired Abscint SA to expand its PET radiodiagnostic pipeline in oncology. This acquisition strengthens Curium's position in the PET imaging diagnostics market.
- LantheusflagshipCurium announced a definitive agreement to merge with Lantheus. This is a major strategic transaction combining two leading radiopharmaceutical companies.
- PeptiDream and PDRadiopharmacoreStrategic collaboration for clinical trial of 64Cu-PSMA-I&T for prostate cancer in Japan. Curium Group, PeptiDream and PDRadiopharma announced completion of patient dosing in this clinical trial.
- Neuroendocrine Cancer Awareness Network (NCAN)corePatient advocacy group providing voice for the NET community by spreading awareness, supporting patients and caregivers, and funding research.
- Learn Advocate Connect Neuroendocrine Tumor Society (LACNETS)corePatient advocacy organization supporting the NET community through education, advocacy, and patient support.
- International Neuroendocrine Cancer Alliance (INCA)coreGlobal alliance of NET patient advocacy organizations working together to raise awareness and support NET cancer patients.
- The Healing NET FoundationcoreFoundation dedicated to improving care for NET cancer patients through education and awareness.
- NETumor Research Foundation (NETRF)coreNon-profit foundation funding research for neuroendocrine tumor treatments and cures.
- NorCal CarciNETminorRegional NET patient advocacy group serving Northern California.
- Pheo Para AllianceminorPatient advocacy organization for pheochromocytoma and paraganglioma.
Scale indicators10 records
Recent moves9 records
Expansion highlights8 records
Monrol competitors and assessment
Company assessmentDirect peers
- Cardinal Health (Nuclear Pharmacy Services): Operates one of the largest nuclear pharmacy networks in the United States, distributing radiopharmaceuticals to hospitals and clinics. Directly comparable to Curium's US PET and SPECT pharmacy footprint and core radiopharmacy distribution model.
- Lantheus Holdings: Public radiopharmaceutical company specializing in diagnostic imaging agents and radioligand therapies (including PYLARIFY for PSMA PET imaging). Announced definitive merger agreement with Curium in August 2026, making it the most directly comparable peer in both diagnostic and therapeutic nuclear medicine.
- Bracco Imaging: Privately held diagnostic imaging company with a global portfolio of contrast agents and radiopharmaceuticals. Comparable to Curium as a focused imaging-diagnostics peer with overlapping nuclear medicine and hospital customer bases, particularly in Europe.
- Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company focused on PSMA PET imaging (Illuccix) and a growing theranostic pipeline. Directly competes with Curium in PSMA-targeted prostate cancer imaging and represents an emerging pure-play comparable in the theranostic space.
Others
- IBA (Ion Beam Applications): Belgian company specializing in proton therapy, radiopharmacy solutions, and cyclotron-based isotope production. Comparable to Curium as an enabling infrastructure provider for the nuclear medicine ecosystem, supplying equipment and production technology that supports radiopharmaceutical manufacturing.
Broad incumbents
- Siemens Healthineers: Global medical technology incumbent offering imaging systems (PET, SPECT, CT, MRI) and adjacent diagnostic solutions. Comparable as a broad incumbent serving the same hospital and nuclear medicine customers, though primarily through imaging equipment rather than radiopharmaceuticals.
- Novartis (Radioligand Therapy): Major pharmaceutical company with leading radioligand therapy franchise (Pluvicto for PSMA-positive prostate cancer and Lutathera for NETs). Directly competes with Curium in theranostic oncology and sets the commercial benchmark for radioligand therapy adoption and pricing.
- GE HealthCare: Diversified medical imaging and diagnostics incumbent with a significant radiopharmacy and PET tracer business alongside its broader imaging equipment portfolio. Comparable to Curium across the PET/SPECT supply chain and nuclear medicine services, though it competes as part of a much wider healthcare portfolio.
- Philips (Image-Guided Therapy / Molecular Imaging): Diversified health technology company with molecular imaging and image-guided therapy businesses serving hospitals. Comparable as a broad incumbent in clinical imaging workflows that consume radiopharmaceuticals, though it does not directly manufacture nuclear medicine products.
- Bayer (Radiology): Pharmaceutical and life sciences company with an established radiology contrast and radiopharmaceutical business (legacy Xofigo). Comparable as a broad incumbent in imaging diagnostics and radiopharmaceuticals, serving overlapping hospital and nuclear medicine customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Monrol social profiles
Digital presenceMonrol compliance and trust
Trust signalCompliance1 record
Monrol financial estimates
Financial estimateRevenue estimate
Valuation estimate
Monrol leadership team
Management profileNumber of profiles
Profiles1 record
Monrol subsidiaries and ownership
Company hierarchySubsidiaries5 records
Monrol funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Monrol M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Monrol
What does Monrol do?
Monrol (operating as Curium Pharma) is a global nuclear medicine company that develops, manufactures, and distributes radiopharmaceuticals for diagnosis and treatment of cancer, cardiovascular, and neurological diseases. Its product portfolio includes radioactive generators, ready-to-use hot products, cold kits for compounding, PET and SPECT imaging agents, targeted radioligand therapies, and auxiliary products. The company operates the world's largest vertically integrated radiopharmaceutical manufacturing network — spanning one molybdenum-99 processing facility, 80 manufacturing sites, and 45+ radiopharmacies across the US and Europe — delivering time-sensitive radiopharmaceuticals to hospitals and nuclear medicine departments in 70+ countries.
Is Monrol a public or private company?
Monrol is a private company. It is classified as private equity controlled and is currently operating.
When was Monrol founded?
Monrol was founded in 1994. It employs 251 to 500 people.
Where is Monrol based?
Monrol is headquartered in Beykoz.
How does Monrol make money?
One revenue line is on record: radiopharmaceutical Products.
Who are Monrol's main competitors?
Direct peers on record are Cardinal Health (Nuclear Pharmacy Services), Lantheus Holdings, Bracco Imaging and Telix Pharmaceuticals. IBA (Ion Beam Applications) is listed as an others. Broad incumbents are Siemens Healthineers, Novartis (Radioligand Therapy), GE HealthCare, Philips (Image-Guided Therapy / Molecular Imaging) and Bayer (Radiology).
Does Monrol have an API?
No public API is recorded for Monrol.
What industry is Monrol in?
Monrol's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC). Its NAICS code is 325412 and its SIC code is 2834.